Many diseases, such as inflammatory and central nervous system disorders, currently have a limited number of effective side-effect free treatments. Citronellol (CT) is a monoterpene alcohol present in the essential oil of several plants used in cooking and traditional medicine, such as those of the genus Cymbopogon and Citrus, with pharmacological activities already described in the literature. The aim of this review was to summarize the pharmacological activities already attributed to CT that could be used in treatments for humans. The databases PubMed, MedLine, Scopus, Lilacs and Scielo were searched using the terms "Citronellol" and "Drug effect". 32 articles were identified and used in the study. Twenty-one articles demonstrated CT activities, including antibiotic and antifungal effects in vitro, and 11 properties including analgesic and anticonvulsant effects in vivo, besides presenting low toxicity. In view of the need to discover new drugs and the activities reported for CT, it can be stated that CT is a promising molecule to target in future pharmacological studies.
antioxidant activity of Lippia alba (Chies et al., 2013) and the analgesic effect of Ocimum basilicum (Nascimento et al., 2015) .
The essential oils of medicinal plants are rich in secondary metabolites whose main function is plant defense. Terpenes are composed of isoprene units and constitute a considerable part of the secondary metabolites found in plants, and have several pharmacological effects already described in the literature, such as the antihyperalgesic activity of citronellal , the anti-inflammatory effects of carvacrol (Lima et al., 2013) and the antioxidant properties of linalool (Seol et al., 2016) . Menthol, an alcoholic monoterpene, has been studied for many years and a number of formulations in which it is present are available on the market. (Eccles, 1994) . In addition to the promising activities already described for terpenes, the possibility of synthesis of these compounds may result in reduced costs and time to discover new drugs (Jansen and Shenvi, 2014). Figure 1 ) is a monoterpene alcohol monoterpene found in the essential oil of plants of the genus Cymbopogon and has several pharmacological activities already described in the literature, such as anticonvulsant, antihyperalgesic and orofacial antinociceptive properties (Renan G. Brito et al., 2015 Brito et al., , 2013a Sousa et al., 2006) . Therefore, in view of the need to identify new sources of drugs that are more effective and have less side effects, and given the fact that citronellol is a terpene whose class has already been found to have a number of beneficial pharmacological effects, this study aimed to review the pharmacological effects already described for citronellol that present possibilities for treatments in humans.
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Methods
This systematic review used a literature search to find all relevant articles published up to June 2017. The search was performed through specialized databases (PubMed, MedLine, Scopus, Lilacs and Scielo -Scientific Electronic Library Online) using a combination of the keywords 'citronellol' and 'drug effects', either as Medical Subject Headings terms (MeSH terms) or as free-text words. Clinical and/or preclinical studies demonstrating some pharmacological activity of citronellol and written in English, Portuguese or Spanish were included in the manuscript. The exclusion criteria were review articles and studies that evaluated pharmacological activities not aimed at the subsequent use of citronellol in humans.
After searching the database using the keywords, 444 texts were identified. Two independent investigators (P.L.S. and J.P.S.C.F.M.) then examined the titles to identify relevant studies and went on to read the abstracts of the selected studies to compare the content with the inclusion and exclusion criteria. Any discrepancies between the selections were resolved by consensus between the investigators.
Results
The studies in this review examine various activities of citronellol. In the initial keyword search 444 articles were identified, distributed as follows in the databases: 129 from PubMed, 198 from Scopus, 117 from MedLine, 0 from Lilacs and 0 from Scielo. After reading the titles and abstracts and assessing the inclusion and exclusion criteria, 77 articles were selected: 31 from PubMed, 19 from Scopus and 27 from MedLine. Of these, 45 articles were indexed in two or more databases, resulting in 32 articles that were used in the study. Tables 1 and 2. <INSERT FIGURE 2>
<INSERT TABLES 1 AND 2> Several activities have been described for CT, such as antibacterial, antifungal and repellent properties in in vitro studies, and cardiovascular, antidiabetic and antinociceptive effects in in vivo studies. A summary of the results obtained by the studies included in the review is given in Table 3.   <INSERT TABLE 3> This review article presents papers that described pharmacological activities of CT relevant to use in humans. In vitro studies investigated possible antibacterial (Echeverrigaray et al., 2008; Mulyaningsih et al., 2011; Ngan et al., 2012; Nostro et al., 2013) , antifungal (Kim and Park, 2012; Mahmoud, 1994; Pereira et al., 2015; Shin, 2003; Shin and Lim, 2004; Viollon and Chaumont, 1994; Zore et al., 2011 ), anti-lice (GonzalezAudino et al., 2011 , repellent (Michaelakis et al., 2014; Semmler et al., 2014) , lipolytic (Choi, 2006) , anti-allergic (Kobayashi et al., 2016 ), anti-inflammatory (Abe et al., 2003 Su et al., 2010) and antispasmodic Vasconcelos et al., 2016) properties. In vivo studies investigated possible cardiovascular (Bastos et al., 2009; Igor A C Menezes et al., 2010; Ribeiro-Filho et al., 2016) , antidiabetic (Jagdale et al., 2016; Srinivasan and Muruganathan, 2016) , anti-cholesterol (Batubara et al., 2015) , antinociceptive Renan G Brito et al., 2013) , antihyperalgesic (Renan G Brito et al., 2015) , anti-anxiety (Umezu et al., 2002) and anticonvulsant (Sousa et al., 2006) activities. Most of the in vitro studies did not describe the isomeric form of CT used in the study. Among those which did describe the isomeric form, 3 reported using only the isomeric form (±) (Mulyaningsih et al., 2011; Su et al., 2010; Vasconcelos et al., 2016) , 1 used (+) and (-) (Ngan et al., 2012) , and 1 used the (+), (-) and (±) forms (Kobayashi et al., 2016) . In vivo studies mainly used the form (-) in studies that aimed to investigate antinociceptive and antihyperalgesic activities (Brito et al., 2012; Renan G Brito et al., 2015) , (±) in studies investigating cardiovascular activities (Bastos et al., 2009; Igor A C Menezes et al., 2010) and (+) for anticonvulsant activity (Sousa et al., 2006) . In the following section, we examine the various properties of CT which were investigated in the studies.
Antibacterial
In 2007, Kotan et al. investigated for the first time the antibacterial activity of CT. The authors used a concentration of 30 mg/ml in the disk infusion method and described the effect of CT on various Gram positive and negative species of clinical relevance, such as Staphylococcus aureus ATCC 29213, Streptococcus pyogenes ATCC 176, Klebsiella pneumoniae, Pseudomonas aeruginosa and Salmonella typhimurium. One year later, Echeverrigarav et al. (Echeverrigaray et al., 2008) demonstrated the antibacterial effect of CT at a lower concentration (Minimal inhibitory concentration -MIC = 3 mg/l), using the broth microdilution method on Proteus mirabilis, which causes urinary tract infections.
The bacteriostatic and bactericidal effects of the racemic mixture (±) of CT were described by Mulyaningsih et al. (Mulyaningsih et al., 2011) , which showed a better effect on Gram-positive (MIC and Minimal bactericidal concentration [MBC] = 0.125 mg/ml) than on Gram-negative bacteria (MIC = 0.125-0.25 mg/ml and MBC = 0.25-0.5 mg/ml), by the microdilution method. Ngan et al. (Ngan et al., 2012) studied the effect of CT in the enantiomer forms (+) and (-), by broth microdilution and noted that (-)-CT (MIC = 0.08-0.62 mg/ml) presented a better effect than (+)-CT (MIC = 0.16-0.62 mg/ml), acting on a greater number of different species.
Nostro et al. evaluated planktonic growth and biofilm formation of bacteria after the addition of CT on single (L. monocytogenes, S. aureus, E. coli, and P. aeruginosa) and mixed populations (E. coli + S. aureus), and found that in both populations high efficacy was maintained over a long (48-240 h) time period.
Antifungal
In 1994, Viollon and Chaumont (Viollon and Chaumont, 1994) (Mahmoud, 1994) described the effect of CT on Aspergillus flavus, a fungus normally found in contaminated food and reported that CT (MIC = 500 ppm) inhibited growth of A. flavus and the formation of aflatoxins B1 and B2, in a concentration of 1000 ppm, when evaluated on the eighth and fifteenth day after incubation. Shin (Shin, 2003) also studied the effect of CT (MIC = 0.78 and 0.79 µg/ml respectively) on A. flavus and A.
niger, but by disk diffusion. A study by Shin and Lim (Shin and Lim, 2004) showed that CT strongly inhibited (MIC = 0.5-2 mg/ml and MFC = 1-4 mg/ml) the Trichophyton species, a cause of superficial mycosis in humans, using disk diffusion. CT also presented a synergic effect (Fractional inhibitory concentration indices [FICI] = 0.18) with ketoconazole.
CT was fungistatic on Candida albicans, probably by causing alterations in morphogenesis (66.6 µg.ml -1 ) with a 76% inhibition of germ tube induction and accumulation of the cells in the S phase of cell cycle. In a study by Zore et al., synergism of CT (MIC: 0.256%) with fluconazole (FICI: 0.046) was observed (Zore et al., 2011 (Mahmoud, 1994) and Shin (Shin, 2003) , described previously.
Finally, Pereira et al. 
Anti-lice
This activity of CT was described by Gonzales-Audino et al. (Gonzalez-Audino et al., 2011) who showed that CT (5%) caused knockdown and mortality in permethrin-resistant adult head lice, Pediculus humanus capitis species, by the immersion method.
Repellent
Michaelakis et al. (Michaelakis et al., 2014) used the sugar-feeding behavioral bioassay to investigate the repellent effect of CT (1 mg cm -2 ) on Culex pipiens, a vector of West Nile virus, and observed 100% repellence. However, CT (0.25-1%) did not present repellent activity on Aedes aegypti, evaluated by biting activity in human volunteers (Semmler et al., 2014) .
Lipolytic
Choi (Choi, 2006) studied the lipolytic activity of citrus peel oils and their components, by in vitro technique, using gas chromatography (GC), and reported that CT presented a low lipolytic effect (about 2%) in a solution of olive oil. The lipolytic effect was verified by the percentage of oleic acid produced from olive oil.
Anti-allergic
The anti-allergic activity of CT was evaluated recently by Kobayashi et al. (Kobayashi et al., 2016) . The authors tested different enantiomers forms of CT (0.5-1 mM) in relation to degranulation and cytokine production by mast cells induced by immunoglobulin E (IgE). (-)-CT (0.5mM) was more effective and inhibited degranulation by 69.4%, while (+)-CT (0.5 mM) inhibited degranulation by 21.3% and (±)-CT (1 mM) by 54.6%. CT significantly inhibited IgE-induced tumor necrosis factor -α (TNF-α) production in murine-cultured mast cells.
Anti-inflammatory
In 2003 (COX-2) protein expression in a dose-dependent manner and suppressed PGE 2 production.
(±)-CT reduced nuclear factor-κB (NF-κB) p65 levels and increased inhibitor of nuclear factor kappa B, alpha (IκBα) in the cells' cytosol.
Antispasmodic
Sadraei et al. described the antispasmodic effect of CT by the method of ileum contraction induced by KCl, acetylcholine (Ach) and electrical field stimulation (EFS). CT was more effective in reducing contraction induced by KCl (IC 50 = 2.9±0.3 µg/ml), the first and second contractions induced by ESF (IC 50 = 5.4±0.9 and 3.4±0.9 µg/ml, respectively), and those induced by ACh (IC 50 = 7.5±1.2 µg/ml), respectively.
Vasconcelos et al. (Vasconcelos et al., 2016) showed an antispasmodic effect of ( Contractions induced by restoration of external Ca 2+ levels after depleting internal Ca 2+ stores also were inhibited by (±)-CT. The antispasmodic effect of (±)-CT was not reversed by L-N G -nitroarginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase, indomethacin and tetraethylammonium, or inhibition of transient receptor potential cation channel subfamily V member 1 (TRPV1) or Transient receptor potential ankyrin-1 (TRPA1).
Cardiovascular effects
The first study to evaluate the effect of CT on the cardiovascular system was developed by Bastos et al. (Bastos et al., 2009 ). The authors reported that (±)-CT was able to reduce blood pressure in normotensive rats, associated with tachycardia. CT-induced tachycardia was reversed with the use of atropine and hexamethonium, however hypotension was maintained. In addition, (±)-CT was able to cause relaxation in the mesenteric artery 
Antidiabetic
Recently, Srinivasan and Murugunathan (Srinivasan and Muruganathan, 2016) demonstrated the antidiabetic effect of CT (25, 50 and 100 mg/kg) on diabetes mellitus induced by streptozotocin, chemical agent that is toxic to the insulin-producing beta cells of the pancreas in mammals. CT reduced food/water intake but body weight increased with less insulin increase than in a control group. Plasma glucose of rats also increased less in the CT group than control group. Treatment with CT (50 mg/kg) inverted the activities of glucose metabolic enzymes and the levels of hemoglobin, glycated hemoglobin, glycogen, and liver and kidney damage biomarkers induced by diabetes. Liver damage and damage in the islets of Langerhans in the pancreas induced by streptozotocin were reduced by the treatment with CT, and insulin-positive cells were increased in diabetic rats (Srinivasan and Muruganathan, 2016 ).
Other authors (Jagdale et al., 2016 ) used the same model and reported that after 45 days of treatment CT (2 mg/kg/day) was able of reduce tissue damage induced by diabetes mainly in the liver, kidney and eye lens of rats. An anti-cataract effect was investigated by in vitro studies and this action of the CT was found to occur simultaneously with an increase in antioxidant enzyme superoxide dismutase, and a reduction in sorbitol level, a sugar produced by the polyol pathway in diabetes. The cell viability of hepatocytes was greater than 90% after administration of CT, indicating that CT did not produce considerable cell death, which would negate the positive effects of CT.
Anti-cholesterol
The anti-cholesterol activity of CT was studied by Batubara et al. (Batubara et al., 2015) , who treated animals subjected to a high fat diet with CT inhalation and plasma cholesterol was reduced. CT did not change the level of the liver enzymes alanine transaminase (ALT) or aspartate aminotransferase (AST).
Antinociceptive
Brito et al. showed the antinociceptive effect of (-)-CT on nociception induced by acetic acid, formalin and hot plate. 
Antihyperalgesic
To investigate the antihyperalgesic effect of (-) 
Anti-anxiety
The anti-anxiety effect of CT was investigated by Umezu et al. (Umezu et al., 2002) using the Geller and Vogel conflict tests in mice. CT was able of increase the response rate during the alarm period in the Geller conflict test and the number of electric shocks in the Vogel conflict test. showing more difficulty in relation to action by this pathway. In addition, the authors observed that (+)-CT (3.2-6.4 mM) depressed the compound action potential in the sciatic nerves of rats, suggesting that the anticonvulsant effect of (+)-CT may be due to a reduction of the action potential amplitude.
Anticonvulsant
Discussion
The lack of effective side-effect free treatments for numerous clinical conditions highlight the need for the discovery and use of new drugs. Examples of these conditions are those which require a treatment against multiresistant microorganisms (Lessem et al., 2015) , in addition to inflammatory and chronic pain conditions, whose existing treatment is not always effective. Severe diseases, such as tuberculosis, present a multi-resistant etiological agent (Lessem et al., 2015) . Chronic inflammatory diseases like arthritis have long-term treatments that can have a number of side effects (Ma et al., 2014) . Chronic pain conditions such as fibromyalgia require effective medications with less side effects to enable a better quality of life for individuals who are affected by these syndromes (Yelland, 2017) .
Previous studies have already demonstrated the benefits of monoterpenes in the treatment of various signs and symptoms, from those of acute manifestations, to those of chronic manifestation, pointing to this class of natural products as an alternative for the development of new drugs (Guimarães et al., 2014 (Guimarães et al., , 2013 Melo et al., 2011; Seol et al., 2016) .
In addition, medicinal products containing terpenes in their formulation are already available in the market, such as menthol used in the treatment of pain, again showing the importance of these products (Pergolizzi et al., 2018) .
In this review, we highlighted the numerous benefits of the use of CT, with activities ranging from the antibacterial to the anticonvulsant. CT was able to act against important microorganisms causing diseases in humans, such as Streptococcus pyogenes, Klebsiella
pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Cryptococcus neoformans,
Candida albicans, and Aspergillus and Trichophyton (Echeverrigaray et al., 2008; Kim and Park, 2012; Mahmoud, 1994; Mulyaningsih et al., 2011; Ngan et al., 2012; Nostro et al., 2013; Pereira et al., 2015; Shin, 2003; Shin and Lim, 2004; Viollon and Chaumont, 1994; Zore et al., 2011) . In addition, CT also showed anti-lice activity (GonzalezAudino et al., 2011) as well as a repellent effect against Culex pipiens, limiting the possible impact caused by the West Nile virus (Michaelakis et al., 2014) . CT showed it was effective against a range of microorganisms, and had characteristics such as anti-lice and repellent properties while not presenting high toxicological activity when tested in in vitro studies, making it a possible source for new medicines Zore et al., 2011) .
In in vitro tests, CT showed low lipolytic activity (Choi, 2006) . This result may explain the low toxicity of CT demonstrated by Gonzales-Audino and collaborators The antispasmodic effect of CT on isolated ileum and tracheal contraction of rats was also described, through action on channels Ca 2+ Vasconcelos et al., 2016) . According to the authors, CT reversed the contraction of ileum induced by KCl (80 mM), electrical field stimulations (EFS) and acetylcholine (ACh, 2 μM). The control used by the authors to reverse the contraction of the ileum induced by KCl was loperamide, an opioid that acts by inhibiting the release of neurotransmitters. Because opioid receptors are present in the ileum and may reduce the influx of Ca 2+ , it is believed that CT has reduced the contractility of the ileum by reducing the influx of Ca 2+ in the presynaptic neuron, like loperamide ).
Vasconcelos et al. (Vasconcelos et al., 2016) reversed by CT, probably via an antioxidant effect thorough an increase of superoxide dismutase enzyme, and the reduction of sorbitol level (Jagdale et al., 2016) . Blood cholesterol was also reduced after the administration of CT, without altering the levels of the liver enzymes ALT and AST, demonstrating the absence of hepatic injury (Batubara et al., 2015) .
CT actions on the central nervous system were also described. The antinociceptive effect in the first phase of the formalin test and in the hot plate test are indicative of this effect. In addition, the effect of CT was reversed by naloxone, suggesting its action on opioid receptors . Another indication of the central action of CT was the its antinociceptive effect on orofacial pain induced by formalin, capsaicin and glutamate, which reinforces the effect of CT on the modulation of Ca 2+ channels, as well as suggesting other possibilities of action, such as the glutamatergic and substance P pathways. When investigating the encephalic areas activated after the administration of CT, activation of the retrosplenial area and the periaqueductal gray matter were observed, both areas of importance in the modulation of pain (Renan G Brito et al., 2013) .
The anti-anxiety (Umezu et al., 2002) and anticonvulsant (de Sousa et al., 2006) actions described for CT again demonstrate the effect of this monoterpene on the central nervous system, which may be derived from a reduction of compound action potential amplitude (de Sousa et al., 2006) .
The studies described several pharmacological activities for CT, and some mechanisms of action have already been defined, especially those involving antiinflammatory (Abe et al., 2003; Renan G Brito et al., 2015; Kobayashi et al., 2016) , antioxidant (Jagdale et al., 2016) and analgesic Renan G Brito et al., 2015;  Renan G. Brito et al., 2013b) pathways (Figure 3 ), indicating this compound as an alternative treatment for such disorders.
One possible explanation for the diversity of CT actions described in the literature could be the presence of pharmacological activity in different isomeric forms. Most of the in vitro studies that described the isomeric form used, opted to use the racemic mixture (Mulyaningsih et al., 2011; Su et al., 2010; Vasconcelos et al., 2016) . In some activities investigated in in vivo studies, such as the cardiovascular ones, the racemic mixture was also preferred (Bastos et al., 2010; Igor A C Menezes et al., 2010) . To investigate the effect of CT on pain sensitivity, (-)-CT was more frequently used Renan G. Brito et al., 2015 , 2013a . (+)-CT rather than (-)-CT was only used in in vivo studies investigating its anticonvulsant effect (Sousa et al., 2006) .
Conclusion
In view of the need for new medicines for various health conditions, we would highlight natural products, especially terpenes, as important alternatives for the development of new drugs. CT's antibacterial, antifungal, antispasmodic, anti-inflammatory, antinociceptive, anticonvulsive and anti-anxiety activities have already been described in the literature, besides presenting low toxicity. The range of pharmacological activities found in CT's different isomeric forms make it a promising molecule to study in many areas of research.
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